脑部放疗，上午比下午敏感许多！! |# L K( J+ y) v( _
9 i9 m8 F, l5 e$ @2 [% h0 e5 V
) z9 F! T& r% N7 @ D
Cancer 2011 Jan 15;117(2):414-20. doi: 10.1002/cncr.25423. Epub 2010 Sep 9.$ ?7 e& w' _3 N: d, J1 s2 {
Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?
" h# D( \3 p4 C9 NRahn DA 3rd, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O'Quigley JM, Rich T.
( S" K: T0 `# N2 f# gSourceDepartment of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA.
* S X' U* ^3 h( c$ E0 y
8 f. ]% d& Z8 _# s* kAbstract m0 M4 q6 J+ h z- d' C, k
BACKGROUND: Circadian cell-cycle progression causes fluctuating radiosensitivity in many tissues, which could affect clinical outcomes. The purpose of this study was to determine whether outcomes of single-session gamma knife radiosurgery (GKRS) for metastatic nonsmall cell lung cancer (NSCLC) differ based on treatment time.- Q; ^0 w1 f# Q4 C' ]- Q% S1 q. g
' A" X1 T+ t6 k2 @
METHODS: Fifty-eight patients received GKRS between 10:00 am and 12:30 pm and 39 patients received GKRS between 12:30 pm and 3:00 pm. The mean peripheral dose was 18.6 Gy. The mean tumor size was 7.3 cm³. Magnetic resonance imaging was used to score local control at 3 months. Cause of death (COD) was categorized as central nervous system (CNS)-related or systemic.
2 @% F- L. i; [& j6 m9 E2 W" A! `/ B
# @2 k7 l0 F$ p- g) hRESULTS: Demographic and disease characteristics of the 2 groups were similar. Local control at 3 months was achieved in 97% (35/36) of patients who underwent GKRS early in the day versus 67% (8/12) of patients who underwent GKRS later in the day (chi-square, P = .014). Early GKRS was associated with better survival (median 9.5 months) than late GKRS (median 5 months) (Kaplan-Meier log-rank test, P = .025). Factors contributing to better survival in a Cox regression model included early treatment time (P = .004) and recursive partition analysis class (P < .001). Cause of death in the early treatment group was CNS-related in 6% (3/47) of patients versus 24% (8/34) of patients in the late treatment group (chi-square test, P = .026).$ Q+ }& a; ^: @3 ]
^* G1 Y0 Z5 X6 O$ \CONCLUSIONS: GKRS for metastatic NSCLC had better local control, better survival, and a lower rate of CNS-related cause of death when given earlier in the day versus later in the day. These retrospective data should encourage future study in brain radiosurgery and non-CNS stereotactic body radiotherapy series.
* m5 r9 E4 i% O, S: m7 y5 ^) d' a9 |, S5 s6 ~4 @6 v% M
|
三代伏美换一代特罗凯获益率问题
家父25年2月因肩膀疼痛确诊肺腺癌晚期4B，双肺转，多发骨转，脑转（非典型），
盲试靶向药 29个月，治疗分享
时间：2025/1/27 盲试靶向药第29个月。
本月治疗方案：7080（14mg）。2024年11月底
奥西替尼耐药后续治疗，出现腹水
治疗经过：
2010确诊腺癌
治疗方案：右肺上叶切除，10年民诺宾2次，顺铂+盖诺2次。
完成手术，病理也出来了，烦请各位老
之前因为心脏问题，去心内造影，前降支75%狭窄，回到心胸外科手术，目前主治医生说是
生存期超4年！首个击败奥希替尼的药
作者：seacat
2025年3月26日，巴黎举行的2025欧洲肺癌大会（ELCC 2025）报道了III期研
/ D5 L$ O) W8 g( H- E3 W- i2 [
显身卡
